Partner Beth Boland is mentioned in a Boston Globe Magazine article, “How the 2017 Women’s March woke ‘the old girls’ network,'” about pioneering women who are helping the next generation of women rise up.
The article notes that Boland took part in the 2017 Women’s March following the election of Donald Trump and that she and a fellow participant, retired corporate executive Gail Deegan, decided afterward to harness their experience and influence to fight for women and families by forming the Boston Women Leaders Network, a diverse group of veteran high achievers from the corporate, civic, and public sectors that is using its members’ relationships to push for changes that will advance women locally.
The article notes that Boland took part in the 2017 Women’s March following the election of Donald Trump and that she and a fellow participant, retired corporate executive Gail Deegan, decided afterward to harness their experience and influence to fight for women and families by forming the Boston Women Leaders Network, a diverse group of veteran high achievers from the corporate, civic, and public sectors that is using its members’ relationships to push for changes that will advance women locally.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”